MX2023006404A - Terapia combinada de anticuerpos y taxanos. - Google Patents
Terapia combinada de anticuerpos y taxanos.Info
- Publication number
- MX2023006404A MX2023006404A MX2023006404A MX2023006404A MX2023006404A MX 2023006404 A MX2023006404 A MX 2023006404A MX 2023006404 A MX2023006404 A MX 2023006404A MX 2023006404 A MX2023006404 A MX 2023006404A MX 2023006404 A MX2023006404 A MX 2023006404A
- Authority
- MX
- Mexico
- Prior art keywords
- combination therapy
- antibody
- taxane combination
- taxane
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122042P | 2020-12-07 | 2020-12-07 | |
| PCT/EP2021/084659 WO2022122765A2 (en) | 2020-12-07 | 2021-12-07 | Antibody and taxane combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023006404A true MX2023006404A (es) | 2023-09-15 |
Family
ID=79165020
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023006404A MX2023006404A (es) | 2020-12-07 | 2021-12-07 | Terapia combinada de anticuerpos y taxanos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240109972A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4255575A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023551980A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230128482A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117083080A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021393908A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200895A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL303424A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006404A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202237081A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022122765A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250020679A (ko) | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| EP4558168A4 (en) * | 2022-07-20 | 2026-07-15 | Biontech Us Inc | POLYTHERAPY INCLUDING A NEOANTIGEN-BASED VACCINE |
| EP4751731A1 (en) * | 2024-11-29 | 2026-06-03 | Affimed GmbH | Combination of a bispecific antibody construct, an immune checkpoint inhibitor and a taxane |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| KR100745488B1 (ko) * | 2006-07-04 | 2007-08-02 | 학교법인 울산공업학원 | 항-4-1bb 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| ES2763429T5 (es) * | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| SMT201900702T1 (it) | 2015-01-08 | 2020-01-14 | Genmab As | Agenti agonistici leganti il recettore del tnf |
| KR20250020679A (ko) * | 2017-08-04 | 2025-02-11 | 젠맵 에이/에스 | Pd-l1 및 cd137에 결합하는 결합제 및 그의 용도 |
| SG11202105152YA (en) * | 2018-11-30 | 2021-06-29 | Abl Bio Inc | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof |
| EP3897612A1 (en) * | 2018-12-19 | 2021-10-27 | Genentech, Inc. | Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor |
-
2021
- 2021-12-07 WO PCT/EP2021/084659 patent/WO2022122765A2/en not_active Ceased
- 2021-12-07 MX MX2023006404A patent/MX2023006404A/es unknown
- 2021-12-07 CN CN202180092643.1A patent/CN117083080A/zh active Pending
- 2021-12-07 CA CA3200895A patent/CA3200895A1/en active Pending
- 2021-12-07 AU AU2021393908A patent/AU2021393908A1/en active Pending
- 2021-12-07 TW TW110145714A patent/TW202237081A/zh unknown
- 2021-12-07 EP EP21834759.9A patent/EP4255575A2/en active Pending
- 2021-12-07 KR KR1020237023103A patent/KR20230128482A/ko active Pending
- 2021-12-07 IL IL303424A patent/IL303424A/en unknown
- 2021-12-07 JP JP2023534290A patent/JP2023551980A/ja active Pending
- 2021-12-07 US US18/038,818 patent/US20240109972A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022122765A2 (en) | 2022-06-16 |
| AU2021393908A9 (en) | 2024-04-18 |
| JP2023551980A (ja) | 2023-12-13 |
| TW202237081A (zh) | 2022-10-01 |
| CA3200895A1 (en) | 2022-06-16 |
| CN117083080A (zh) | 2023-11-17 |
| IL303424A (en) | 2023-08-01 |
| KR20230128482A (ko) | 2023-09-05 |
| US20240109972A1 (en) | 2024-04-04 |
| WO2022122765A3 (en) | 2022-08-11 |
| EP4255575A2 (en) | 2023-10-11 |
| AU2021393908A1 (en) | 2023-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201907225B (en) | Treatment of her2 positive cancers | |
| WO2022122765A3 (en) | Antibody and taxane combination therapy | |
| ZA202006481B (en) | Anti-msr1 antibodies and methods of use thereof | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| PH12019501663A1 (en) | Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate | |
| MX2020006116A (es) | Terapia combinada de agonistas de icos dirigidos a tumores con moleculas biespecificas de linfocitos t. | |
| MX2020009842A (es) | Uso de conjugados de anticuerpo-farmaco que comprenden agentes interruptores de tubulina para tratar tumor solido. | |
| SA523442921B1 (ar) | جزيئات ربط علاجية | |
| MX2022015748A (es) | Uso de una molecula anti-b7-h3 en combinacion con una molecula anti-pd-1 en la preparacion de formulaciones para el tratamiento de cancer. | |
| MX2022003005A (es) | Composiciones y metodos de anticuerpos anti-cd39. | |
| MX2023002805A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos. | |
| PH12022551960A1 (en) | Antibodies binding to b7h4 | |
| MX2021000726A (es) | Terapia combinada de gen de activacion de linfocitos 3(lag-3) para el tratamiento del cancer. | |
| MX2023008849A (es) | Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico. | |
| MX2024000674A (es) | Agentes de union multiespecificos contra cd40 y cd137 en terapia de combinacion. | |
| PH12020551556A1 (en) | Drug conjugates of cmet monoclonal binding agents, and uses thereof | |
| PE20221830A1 (es) | Anticuerpos especificos contra la claudina 18.2 tumoral | |
| ZA201907754B (en) | Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer | |
| MX2023008285A (es) | Conjugado de anticuerpo anti-dll3-farmaco. | |
| MX2024002069A (es) | Anticuerpos anti-hla-g. | |
| MX2025007378A (es) | Inhibidores de ctps1 para usarse en el tratamiento de cancer deficiente de ctps2 | |
| IL327342A (en) | Combination of anti-claudin 18.2/anti-4-1BB antibodies and a second therapeutic agent in the treatment of cancer | |
| ZA202302151B (en) | Modified ezetimibe drug for cancer treatment | |
| WO2021062085A8 (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies | |
| EP4706653A3 (en) | Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers |